Patents Examined by Phillip Gambel
  • Antibodies to CD40 with enhanced agonist activity
    Patent number: 10894835
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: January 19, 2021
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Rony Dahan
  • Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
    Patent number: 10888608
    Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: January 12, 2021
    Assignee: Bellicum Pharmaceuticals, Inc.
    Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
  • Anti-C5a receptor antibodies
    Patent number: 10882916
    Abstract: The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 5, 2021
    Assignee: NOVO NORDISK A/S
    Inventors: Kristian Kjaergaard, Soeren Lund, Stefan Zahn, Louise H. Zeuthen, Anker J. Hansen
  • CD40L binding polypeptide
    Patent number: 10882911
    Abstract: Disclosed is a CD154 binding polypeptide that specifically recognizes CD154. The polypeptide according to the present disclosure effectively inhibits the CD154-CD40 interaction without activating platelets, and thus can be effectively used in the prevention or treatment of various T cell-mediated or antibody-mediated diseases or symptoms, which requires inhibition of the interaction.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 5, 2021
    Assignee: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: SeongHoe Park, Kyeong Cheon Jung
  • Anti-CD154 antibody having improved binding, functional and safety characteristics
    Patent number: 10874738
    Abstract: Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: December 29, 2020
    Assignee: IMMUNEXT INC.
    Inventors: Jay Rothstein, Robert George Edward Holgate, Arron Hearn
  • Fully human antibody against human CD 137
    Patent number: 10875926
    Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: December 29, 2020
    Assignee: Dingfu Biotarget Co., Ltd.
    Inventors: Ting Xu, Yan Luan, Xiaoxiao Wang, Jianjian Peng, Shuli Ma, Hui Ma, Xiaolong Pan, Shilong Fu, Shanshan Ning, Yeqiong Fei, Meng Zhao
  • Nucleic acids encoding anti-Factor P antibodies
    Patent number: 10865237
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 15, 2020
    Assignee: NOVARTIS AG
    Inventors: Leslie Ngozi Anuna Johnson, Ute Jaeger, Yong-In Kim, Christian Carsten Silvester Kunz, Igor Splawski, Michael Roguska, Joy Ghosh, Barbara Brannetti, Michael Stefanidakis, Sha-Mei Liao
  • Complement factor H antibodies
    Patent number: 10865238
    Abstract: Disclosed herein are Complement factor H (CFH) antibodies and methods of using the antibodies.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: December 15, 2020
    Assignee: Duke University
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, Michael Anthony Moody
  • Nucleic acids encoding agonistic antibodies that bind CD40
    Patent number: 10865244
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: December 15, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties and related therapies
    Patent number: 10858439
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: December 8, 2020
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Randolph J. Noelle
  • Methods of treating hemolytic disorders comprising administering an anti-C3b antibody
    Patent number: 10858420
    Abstract: A method of treating a hemolytic disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of an antibody that binds to a component of alternative pathway C3 convertase and selectively inhibits C3a, C5a, C3b, C5b, and C5b-9 produced exclusively by the alternative pathway, without inhibiting any of the classical pathway's ability to produce C3a, C5a, C3b, C5b, and C5b-9.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 8, 2020
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Nucleic acids encoding an anti-CD40 antibody
    Patent number: 10844130
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 24, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • Anti-CD40 antibody
    Patent number: 10844131
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: November 24, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Methods of immune therapy with anti-CD154 antibodies having Fc modifications
    Patent number: 10822423
    Abstract: Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: November 3, 2020
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Randolph J. Noelle
  • Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
    Patent number: 10813917
    Abstract: The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: October 27, 2020
    Assignee: MedRegen, LLC
    Inventors: Zhaoli Sun, George Melville Williams
  • Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab
    Patent number: 10815296
    Abstract: Disclosed are drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA, also called TA-TMA) in a subject that has undergone an HSCT. Also disclosed are methods of using drugs capable of inhibiting the complement pathway for use for treating hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy (HSCT-TMA) in a subject that has undergone an HSCT.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: October 27, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Sonata Jodele, Benjamin L. Laskin
  • Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells
    Patent number: 10799553
    Abstract: The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting cells (APCs), preferably provided as an intermixture. The APCs are modified to express immune modulating molecules. Immunization with the vaccine composition of present invention into a subject, induces the host immune system to respond and generate efficient immunity against either pre-existing disease or protect the host against the disease.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: October 13, 2020
    Inventor: Mallen Huang
  • Methods of treating by administering anti-kit antibodies
    Patent number: 10793639
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: October 6, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
  • Single-chain CD40-receptor agonist proteins
    Patent number: 10793616
    Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: October 6, 2020
    Assignee: Apogenix AG
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Tim Schnyder
  • Methods of treating by administering anti-kit antibodies
    Patent number: 10781267
    Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: September 22, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry